This morning’s report on unemployment has cooled enthusiasm for shares across the board. Solar stocks are, for the most part, no exception. Yingli Green Energy Holding Co. Ltd. (YGE) is down nearly...
Bioceres has disclosed ownership of 50.2% of Bioceres Crop Solutions stock.
Fears for a supply shortage of corn earlier this year led the world’s farmers to plant more of the crop on expectations of higher prices. Now that the crop is in, it turns out to be a sixth...
There has been a ‘agribusiness ETF’ for some time via the Market Vectors Agribusiness ETF (NYSE: MOO).  Now we have a new variation and that is the IQ Global Agribusiness Small Cap ETF (NYSE:...
The projected US corn crop is currently in worse condition than it’s been in since 2002, which were then the worst since 1990. Only 56% of this year’s crop was judged to be in “good” or...
When you see sectors that have been key leaders fall it’s often just another buying opportunity.  But when you start seeing an exodus you have to wonder if letting the good times roll is...
Friday is turning out to be a big day with many stocks on the move for an options expiration date.  Some of the big shares with news and on the move are as follows: Adobe Systems Inc. (NASDAQ:...
Today’s commodities report focuses on rising costs for fertilizer and food, the drought in the US southwest, and reports that China is re-selling some of its coal imports. Earlier today we noted...
US equity markets opened solidly higher this morning, but began to lose momentum by mid-morning. From there it’s been a mostly downhill day with the DJIA creeping back to nearly flat with about an...
Today’s alternative energy watch begins with a look at the IPO filing by solar thermal maker BrightSource and then examines a new roadmap for biofuels offered up by the International Energy Agency....
The three major U.S. stock indexes opened mixed this morning, taking until mid-morning to rise above the flat line and stay above it for the rest of the day. The initial response to Bank of Japan’s...
Corbus Pharmaceuticals has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.
Corbus Pharmaceuticals announced that the FDA has designated as a Fast Track development program and granted Orphan Drug Designation to the its investigational new drug Resunab.
Corbus Pharmaceuticals may have found its saving grace in a Fast Track designation from the U.S. Food and Drug Administration (FDA).